SCHEMBL4520307

SCHEMBL4520307

FC(F)(F)c1cc(I)ccc1OCCN1CCCC1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C19 P33261 1/20 0.51
HSD17B10 Q99714 1/20 0.51
LTA4H P09960 6/20 0.51
PTGS2 P35354 1/20 0.51
KDM4E B2RXH2 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.48
HTR2A P28223 1/20 0.47
HTR2C P28335 1/20 0.47
HTR2B P41595 1/20 0.47
DRD2 P14416 3/20 0.46
TDP1 Q9NUW8 1/20 0.44
TSHR P16473 1/20 0.43
CTSS P25774 1/20 0.43
CTSK P43235 1/20 0.43
ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28407170 0.93 CTSS (0.49) CYP1A2CYP2D6CYP2C19HSD17B10LTA4H
SCHEMBL18763502 0.88 HTR2A (0.50) KDM4EHTR2AHTR2CHTR2BDRD2
SCHEMBL4270618 0.83 CYP1A2 (0.51) CYP1A2CYP2D6CYP2C19HSD17B10LTA4H
SCHEMBL14453570 0.83 SMN1; SMN2 (0.66) CYP1A2CYP2D6CYP2C19HSD17B10LTA4H
SCHEMBL2329094 0.83 MEN1 (0.56) CYP1A2CYP2D6CYP2C19HSD17B10LTA4H
SCHEMBL30950884 0.83 CYP1A2 (0.51) CYP1A2CYP2D6CYP2C19HSD17B10LTA4H
SCHEMBL18763402 0.83 CTSS (0.56) HTR2ADRD2CTSSCTSKALDH1A1
SCHEMBL4521633 0.82 KDM4E (0.48) CYP1A2CYP2D6CYP2C19HSD17B10LTA4H
SCHEMBL18763411 0.82 KDM4E (0.52) CYP1A2CYP2D6CYP2C19KDM4EHTR2A
SCHEMBL2324209 0.81 LTA4H (0.61) CYP1A2CYP2D6CYP2C19HSD17B10LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8618132-B2 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2013-12-31 US disclosed
EP-1558578-B1 NOVEL ALKYNE COMPOUNDS HAVING AN MCH ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING THESE COMPOUNDS BOEHRINGER INGELHEIM PHARMA (DE) 2013-03-13 EP disclosed
US-20090069282-A1 ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-03-12 US disclosed
US-7452911-B2 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2008-11-18 US disclosed
US-20040209865-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069282-A1 ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS MCHR1, MCHR2, GPR119 CYP1A2 1859/4885CYP2D6 2280/4885CYP2C19 3472/4885
US-20040209865-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds MCHR1, MCHR2, NPY1R CYP1A2 1449/4885CYP2D6 1797/4885CYP2C19 3629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.